

Publikationen 2018

Originalarbeiten

1. Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, Johnson SR, Daikh D, Dörner T, Aringer M, Bertsias G, SLE Classification Criteria Steering Committee. Performance of Anti-nuclear Antibodies for Classifying Systemic Lupus Erythematosus: a Systematic Literature Review and Meta-regression of Diagnostic Data. **Arthritis Care Res (Hoboken)** 2018; 70: 428-438. Impact factor 3,319.
2. Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erlar A, Behrens F, Burmester GR, Dörner T. Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen: Ergebnisse eines nationalen Registers (GRAID2). **Z Rheumatol** 2018; 77: 28-39. Impact factor 0,716.
3. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N. Trial of Tocilizumab in Giant-Cell Arteritis. **N Engl J Med** 2017; 377: 317-328. Impact factor 72,406.
4. Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. Developing and Refining New Candidate Criteria for SLE Classification: An International Collaboration. **Arthritis Care Res (Hoboken)** 2018; 70: 571-581. Impact factor 3,319.
5. Albrecht K, Huscher D, Buttgereit F, Aringer M, Hoese G, Ochs W, Thiele K, Zink A. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. **Rheumatol Int** 2018; 38: 569-577. Impact factor 1,824.
6. Schmajuk G, Hoyer BF, Aringer M, Johnson SR, Daikh DI, Dörner T, SLE classification criteria steering committee, the international SLE expert panel of the initiative. Multi-center Delphi Exercise Reveals Important Key Items for Classifying Systemic Lupus Erythematosus. **Arthritis Care Res (Hoboken)** 2018; 70: 1488-1494. Impact factor 3,319.

7. Leuchten N, Milke B, Winkler-Rohlfing B, Daikh D, Dörner T, Johnson SR, Aringer M, on behalf of the SLE Classification Criteria Steering Committee. Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. **Lupus** 2018; 27: 1431-1436. Impact factor 2,454.
8. Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, Foeldvari I, Haas JP, Klein A, Tatsis S, Tenbrock K, Zink A, Klotsche J. The time of DMARD start in juvenile idiopathic arthritis determines the likelihood of a drug-free remission in young adulthood. **Arthritis Care Res (Hoboken)** 2018 Jul 25 Epub. Impact factor 3,319.
9. Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. **Arthritis Res Ther** 2018, 20: 174. Impact factor 4,121.
10. Lützner J, Lange T, Schmitt J, Kopkow C, Aringer M (DGRh), Böhle E (ZVK), Bork H (DGOU), Dreinhöfer K (DNVF), Friederich N (Deutsche Arthrose-Hilfe e. V), Gravius S (DGOOC), Heller KD (BVOU), Hube R (DKG), Gromnica-Ihle E (Deutsche Rheuma-Liga Bundesverband e. V), Kirschner S (AE), Kladny B (DGOU), Kremer M (DGU), Linke M (Deutsche Gesellschaft für Medizinische Psychologie), Malzahn J (AOK Bundesverband), Sabatowski R (Deutsche Schmerzgesellschaft e. V), Scharf HP, Stöve J, Wagner R (DGORh), Günther KP. S2k-Leitlinie: Indikation Knieendoprothese Evidenz- und konsensbasierte Indikationsstellung in der KnieEndoprothetik (EKIT-Knie). **Orthopäde** 2018; 47: 777-781. Impact factor 0,632.
11. Leuchten N, Aringer M. Tocilizumab in the treatment of giant cell arteritis. **Immunotherapy** 2018; 10: 465-472. Impact factor 2,716.
12. Aringer M, Denton C. Systemic sclerosis phase III clinical trials - hope on the horizon? **J Scleroderma Relat Disord** 2018; 3: 193-200.
13. Aringer M, Dörner T. Systemischer Lupus erythematosus (SLE) – neue Klassifikationskriterien. **Dtsch Med Wochenschr** 2018; 143: 811-814. Impact factor 0,552.
14. Aringer M, Schulze-Koops H. Immunologie der entzündlichen Systemerkrankungen. **Orthopäde** 2018 Nov; 47: 891-897. Impact factor 0,632.
15. Jansen TL, Perez-Ruiz F, Tausche AK, Richette P. International position paper on the appropriate use of uricosurics with the introduction of lesinurad. **Clin Rheumatol** 2018; 37: 3159-3165.
16. Reuss-Borst M, Tausche AK. [Update on Gout and Calcium pyrophosphate deposition (CPPD)]. **Dtsch Med Wochenschr** 2018 Aug; 143: 1157-1166.
17. Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F,

Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, Pinheiro GDRC, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N. Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout. **Arthritis Care Res (Hoboken)** 2018 May 25. doi: 10.1002/acr.23607.

18. Webers C, Essers I, van Tubergen A, Braun J, Heldmann E, Baraliakos X, Boonen A. Valuing treatment with infliximab for ankylosing spondylitis using a willingness-to-pay approach. **Arthritis Care Res (Hoboken)** 2018; 70: 608-616.
19. Fiehn C, Unger L, Schulze-Koops H, Proft F, Henes JC, Jacobi A, Dörner T. Rituximab zur Behandlung von Poly- und Dermatomyositis. **Z Rheumatol** 2018; 77: 40-45.
20. Venhoff N, Proft F, Schulze-Koops H, Holle J, Voll RE, Iking-Konert C, Jacobi AM, Henes J, Unger L, Kneitz O, Dörner T, Thiel J. Off-label-Biologikatherapie von ANCA-assoziierten und nicht-ANCA-assoziierten Kleingefäßvaskulitiden. **Z Rheumatol.** 2018; 77: 21-27.

Buchkapitel

1. Hanson EP, Schwartz DM, Bonelli M, O'Shea JJ, Aringer M. Signal Transduction in immune cells. In Hochberg M, Silman A, Smolen S Weinblatt M, Weisman M, eds: Rheumatology. **Elsevier** 2018; 79-85.
2. Aringer M. Essential and optional drugs for rheumatic diseases. In Handbook of systemic autoimmune diseases, volume 15 (Atzeni F, Sarzi-Puttini P series eds): Atzeni F, Masala IF, Alteaha D, Lee M, Baraliakos X, eds: Surgery in rheumatic and musculoskeletal disease. **Elsevier** 2018: 78-93.